Jordi bruix biography

Featured publications

• Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

  Authors:

  Finn RS; Merle P; Granito A; Huang YH; Bodoky G;

  (...)

  Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J.

  Reference: Journal Of Hepatology 2018.

• Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

  Authors:

  Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V;

  (...)

  Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J .

  Reference: Lancet Oncology 2018.

• Hepatocellular carcinoma

  Authors:

  Forner A; Reig M; Bruix J;

  Reference: Lancet 2018.

• Complete response under sorafenib in patients with hepatocellular carcinoma.

  Relationship with dermatologic adverse events.

  Authors:

  Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F;

  (...)

  Huertas C; Minguez B; Ayuso C; Bru